Close Menu

NEW YORK – Immunogenomics startup Immunis.AI, once called OncoCell MDx, is eyeing the commercial launch of its prostate cancer surveillance laboratory-developed test, which leverages its immune-based liquip biopsy platform, by early 2021, the company said.

The Royal Oak, Michigan-based firm also aims to finalize an independent validation study for the prostate cancer signature assay within the next two months.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.